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Summary
Objective: Although available nonsurgical pharmacotherapies for treatment of osteoarthritis (OA) are considered to be solely symptom-
modifying agents, recent advances have been made in the search for agents that may modify disease progression. Intra-articular hyaluronan
(HA) therapy is one symptom-modifying approach that has been found to be safe and effective for reducing pain due to OA of the knee.
Presented here is a review of the evidence that HAs may also modify the rate of OA disease progression in addition to providing symptomatic
efﬁcacy.
Design: A review of the literature based on a MEDLINE search through June 2004, using the terms HA, sodium hyaluronate, hyaluronic acid,
hylan, hylan G-F 20, OA, disease modiﬁcation, structure modifying and joint structure.
Results: Evidence for disease-modifying activity of HAs stems from 1) the complex biochemical effects of HAs in the synovium and
extracellular matrix of the articular cartilage, including interactions between exogenously administered HA and articular cartilage, subchondral
bone, matrix proteoglycans, and collagens; 2) the effects of HA administration in animal models of OA, including total or partial meniscectomy
and anterior cruciate ligament transectomy; 3) results of clinical trials using one HA, Hyalgan (sodium hyaluronate, molecular weight
500e730 kDa) that evaluated structural outcomes, such as joint-space width, chondrocyte density and vitality, and arthroscopic evaluation of
chondropathy.
Discussion: Growing preclinical and clinical evidence supports the notion that, in addition to relieving the symptoms of OA, HAs also modify
the structure of the diseased joint and the rate of OA disease progression, at least early in the evolution of the disease process.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SYMPTOM MODIFICATION VS MODIFICATION OF DISEASE
PROGRESSION IN THE TREATMENT OF OSTEOARTHRITIS
Nonsurgical treatments for osteoarthritis (OA) may be
characterized as symptom-modifying or disease-modifying
drugs. As deﬁned by the Osteoarthritis Research Society
(OARS), disease-modifying drugs are those that are
intended to prevent, retard, stabilize, or reverse develop-
ment of the morphological changes of OA1. At present, no
pharmacological treatments for OA are approved for the
indication of modifying the rate of OA disease progression.
However, evaluation of novel agents and agents with
established symptom-modifying activity for disease-modify-
ing effects has become a major focus of research in
musculoskeletal diseases. The orally administered supple-
ments glucosamine and chondroitin sulfate, natural compo-
nents of articular cartilage, are examples of nutritional
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associated with OA and have an impact on OA disease
progression as measured by effects on joint-space width
(JSW)2e4.
Intra-articular (IA) hyaluronan (HA) is currently indicated
only as a symptom-modifying treatment for OA of the knee.
However, there is substantial evidence suggesting that HA
in certain patient populations can also have disease-
modifying activity. This possibility was initially suggested
by the ﬁnding that the pain-relieving beneﬁt of IA HA
generally persists for considerably longer than its half-life
within the injected joint, which has been estimated to be as
short as 18 to 24 h in animal studies5. For example, clinical
efﬁcacy in randomized, controlled trials (RCTs) has been
demonstrated to last for at least 26 weeks for Hyalgan*
*We have chosen to include the branded names, not as an
endorsement or condemnation of a brand, but to offer clarity
regarding clinical data, utilization, and recommendations. The
members of this class can be differentiated by administered dose,
dosing regimens, molecular weight, labeling and supporting clinical
data. However, they share similar terminology for their generic
names with the names that describe the class, and in addition some
share the same generic device name. This can lead to confusion
and misinterpretation, and we have felt compelled to clarify.6
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500e730 kDa)6,7y, and may last as long as a year or more
in some patients8,9. Similarly, Synvisc (hylan G-F 20,
average MW O6000 kDa)10 (Genzyme Biosurgery, Cam-
bridge, MA), Supartz (sodium hyaluronate, average MW
630e1120 kDa)11 (Seikagaku Corporation, Tokyo, Japan),
and Orthovisc (sodium hyaluronate, average MW
1900e3000 kDa)12 (Anika Therapeutics, Woburn, MA) have
also demonstrated months of pain relief. All of these
products are approved for use in the US, although there
are clear distinctions in dose, dosing regimen and labeling
for repeat treatment12e15.
Presented here is a review of preclinical and clinical
evidence that HAs, in addition to relieving pain associated
with OA, also may modify the rate of OA disease
progression.
Methods
References reviewed were taken from MEDLINE, based
on a search through June 2004, using the terms HA,
sodium hyaluronate, hyaluronic acid, hylan, hylan G-F 20,
OA, disease modiﬁcation, structure modifying and joint
structure. Papers were subjectively evaluated for inclusion
based on relevance to the objectives of this review. Data
reported at professional conference proceedings were also
considered. Only a limited selection of nonclinical, bio-
chemical data on HA effects in the joint were included, as
a thorough review of this extensive area was beyond the
scope of this article; an emphasis was placed on studies
that evaluated joint structure outcomes in animal models of
OA and in patients with OA. No ‘‘data on ﬁle’’ information
was considered in this review.
Results
PROPERTIES OF HAs
HAs are found in synovial ﬂuid and many other
extracellular matrices, and play a major role in the pliable
and resilient nature of articular cartilage16 and for mainte-
nance of the viscoelastic and lubricating properties of the
synovial ﬂuid17. The ﬁnding that HA concentration and
chain length (MW) are both reduced in patients with OA of
the knee17 led to the hypothesis that decreased viscosity of
the synovial ﬂuid may cause the wear and pain associated
with the disease. This formed the initial premise for the
development of IA injections of HA as a ﬂuid replacement
treatment termed ‘‘viscosupplementation’’, as therapy for
the treatment of pain associated with OA18. IA HA therapy
with various products of MW greater than 500 kDa has been
shown to be safe and effective in clinical trials6,7,11,19e24
and clinical practice experience25e28 for the relief of pain
associated with OA of the knee.
Aside from the established symptomatic efﬁcacy of
exogenously administered HAs in OA, it has become
increasingly clear that these molecules do more than simply
lubricate and protect the joint from a biomechanical
standpoint. There is now a large body of nonclinical
evidence for complex effects of HAs on joint biochemistry,
as well as preclinical data for all products and clinical
evidence for disease-modifying activity of at least one HA
yFidia SpA, Padua, Italy. Note that discussion of hyaluronans in
this review is primarily limited to US-approved products.product, Hyalgan (sodium hyaluronate, MW
500e730 kDa)14.
Effects of HAs on joint biochemistry
HAs have been shown to regulate many processes in the
synovial ﬂuid, the articular cartilage, and the subchondral
bone, through effects on the matrix proteoglycans, colla-
gens, and hyaladherins in synoviocytes, chondrocytes and
inﬂammatory cells (reviewed in Ref.29e32). By virtue of
these complex effects, potential disease-modifying effects
of exogenously administered HA include regulation of joint
repair by effects on chondrocyte growth and metabolism;
regulation of endogenous HA, proteoglycan and collagen
synthesis; inhibition of expression and function of chon-
drodegrading enzymes; regulation of programmed cell
death (apoptosis); and inhibition of destructive inﬂammatory
responses (Table I). Although it is beyond the scope of this
article to thoroughly review the complex biochemical
activities of HA, some key examples of studies that have
investigated these effects in in vitro and animal models of
OA are discussed here or in referenced reviews.
Creamer et al.33 evaluated the effects of 5 weekly IA
injections of Hyalgan (sodium hyaluronate, MW
500e730 kDa) on concentrations of keratan sulfate, chon-
droitin sulfate, and C-propeptide of type II collagen (bio-
chemical markers of cartilage degradation) in the synovial
ﬂuid of 12 patients with OA of the knee. Over the 6-week
study period, HA produced a trend toward reduced
concentrations of keratan sulfate in the treated knees,
although the difference was not statistically signiﬁcant,
perhaps because of the small sample size or the short time
course of the study. In a rabbit model of OA, IA injections of
Artz (sold as Supartz in US, sodium hyaluronate, MW
620e1170 KDa)15 following anterior cruciate ligament
transectomy (ACLT) were found to suppress synovial
expression of proinﬂammatory cytokine IL-1b and the matrix
metalloproteinase-3 (MMP-3; stromelysin), which degrades
extracellular matrix components proteoglycan and type II
collagen34. A more recent study further demonstrated that
treatment of human articular cartilage explants with an 800-
kDa form of sodium hyaluronate inhibited IL-1b-stimulated
production of three degradative enzymes, MMP-1, MMP-3,
and MMP-13, possibly through interaction between the HA
and CD44 on chondrocytes35. Expression of these mole-
cules in the synovial ﬂuid and cartilage correlates with
inﬂammatory destruction of cartilage in patients with
OA36,37. In studies using the ACLT model in rabbits, HA
injections were also shown to inhibit chondrocyte apoptosis
and histomorphologically measured cartilage degrada-
tion38,39. A recent study using a rabbit partial meniscectomy
model of OA demonstrated that injection of Orthovisc
Table I
Potential disease-modifying activities of hyaluronans
Promotion of healing and repair
Stimulation of chondrocyte growth and metabolism
Maintenance of chondrocyte vitality (decreased apoptosis)
Stimulation of synthesis of articular cartilage matrix components
(e.g., collagen, proteoglycans, including endogenous hyalur-
onan, hyaladherins)
Inhibition of destruction
Inhibition of expression and activity of chondrodegradative
enzymes (e.g., metalloproteinase)
Inhibition of matrix-destructive inﬂammatory processes
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proteoglycan content40 in the tibial condylar articular
cartilage, compared to injection of vehicle.
Anti-inﬂammatory properties of exogenously adminis-
tered HAs include inhibition of leukocyte migration, in-
hibition of leukocyte phagocytosis, inhibition of lymphocyte
proliferation, inhibition of prostaglandin production, pre-
vention of oxidative damage by free radicals, and inhibition
of the expression of inﬂammatory cytokines31. The effects
of Hyalgan (sodium hyaluronate, MW 500e730 kDa)
injections on inﬂammatory mediators in the synovial ﬂuid
have also been demonstrated in patients with OA. In
a randomized, double-blind, saline-controlled study involv-
ing 40 patients with OA of the knee, Corrado et al.41 found
that ﬁve IA injections signiﬁcantly decreased the numbers of
activated macrophages and lymphocytes in synovial ﬂuid,
compared with saline injections. Likewise, Dougados
et al.20 demonstrated that at 4 weeks after the last of four
IA injections, patients who received Hyalgan (sodium
hyaluronate, MW 500e730 kDa) had signiﬁcantly less
synovial effusion, indicating a lesser degree of destructive
inﬂammation.
Any or all of the biochemical effects of HA discussed here
could form the basis for modiﬁcation of OA disease
progression. Moreover, these activities of HA have impli-
cations for other joint disease processes that result in
cartilage damage. The results of a number of preclinical
studies, described in the following section, provide evidence
that these or other activities of HA have the potential to
modify the OA disease process.
PRECLINICAL: ANIMAL STUDIES OF JOINT STRUCTURE
MODIFICATION BY HA
A number of animal models have been developed to
experimentally induce changes associated with OA, such
as the degradation of collagen and proteoglycans of the
articular cartilage, and increased inﬂammation. The most
commonly studied models have been total or partial
meniscectomy and ACLT, and it should be noted that these
models are quite aggressive in that the degenerative
changes can occur within a few months after induction.
Potential disease-modifying activities of exogenously added
HAs have been demonstrated in several species using
these approaches (Table II).
The disease-modifying effects of HA have been evalu-
ated using a meniscectomy model in rabbits and sheep.
Administration of Artz (sodium hyaluronate, MW 620e
1170 kDa), after partial meniscectomy in rabbits or sheep
signiﬁcantly inhibited cartilage degeneration42,43. Five
weekly IA injections of sodium hyaluronate, initiated
immediately after partial or total meniscectomy, signiﬁcantly
enhanced collagen remodeling compared with saline treat-
ments44,45.
Wiig et al.46 reported that a single injection of Healon
(sodium hyaluronate, MW 1900e3900 kDa) (Pharmacia &
Upjohn, Uppsala, Sweden) given immediately after ACLT in
rabbits signiﬁcantly enhanced tissue repair, increased
collagen synthesis, increased angiogenesis, and decreased
inﬂammation compared with a single injection of saline. A
course of 5 weekly injections of Artz (Supartz, sodium
hyaluronate, MW 620e1170 kDa) protected chondrocytes
from apoptotic cell death following ACLT in rabbits38.
Administered to either rabbits or dogs after ACLT, Artz
(Supartz, sodium hyaluronate, MW 620e1170 kDa) also
reduced the degree of damage to the femoral cartilage and
helped to preserve articular cartilage and synovial tissueintegrity39,47. In a study that evaluated the effects of Synvisc
(hylan G-F 20, MW 6000 kDa) (Biomatrix, Montreal,
Canada) in a dog ACLT model, gross morphological and
histological damage within joints that received injections
was signiﬁcantly milder than that seen in control joints48.
Similar results were obtained in rabbits and dogs using
Hyalgan (sodium hyaluronate, MW 500e730 kDa). A
course of 5 weekly Hyalgan injections, starting at 4 or 13
weeks after ACLT, signiﬁcantly reduced the degree of
articular degeneration at evaluations 26 weeks after
surgery. In this study, rabbits that received 10 injections
showed less disease progression than did rabbits treated
with ﬁve injections, suggesting that sequential courses of
Hyalgan therapy may provide long-term beneﬁts for altering
the disease course49. In dogs, initiation of weekly IA
injections of sodium hyaluronate starting at 3, 6, or 12
weeks after ACLT (the Pond-Nuki model of OA) signiﬁcantly
inhibited formation of a ﬁbroblast-like cell layer on the
articular cartilage and increased mean chondrocyte density
and area in the middle and deep layer of the articular
cartilage50. Hyalart (sodium hyaluronate, MW
500e750 kDa)z signiﬁcantly reduced cartilaginous lesions
when given starting at 3, 6, or 12 weeks after ACLT in dogs
(Pond-Nuki model of OA)51.
MW OF HAs AND BIOLOGICAL ACTIVITY
Initial evidence that the MW of injected HA can have
a substantial impact on its biological activity was demon-
strated by Smith and Ghosh52. They found that synthesis of
HA by human synovial cell lines was increased by the
addition of exogenous HA, and that a maximal effect was
achieved using HA preparations with MW between 500 and
approximately 4000 kDa; preparations of less than 500 kDa
had no effect, and with HA preparations of 4700 kDa or
more, the stimulation declined with increasing HA concen-
tration. These investigators proposed that with exogenously
added HA of MW !500 kDa, only weak binding of HA to
cell surface HA receptors can occur; between 500 and
4000 kDa, HA binding to its receptors is optimal; at MWs
O4000 kDa, steric hindrance by the large domains of the
HA molecules prevents optimal receptor occupation.
A recent preclinical study provided further in vitro ﬁndings
that the MW of the HA preparations used may have an
inﬂuence on their potential disease-modifying effects.
Ghosh et al.53 reported that IA treatment of meniscectom-
ized sheep with Hyalgan (sodium hyaluronate, MW
500e730 kDa) but not Hylartil (sodium hyaluronate, MW
3000e6900 kDa, a veterinary product) (Pharmacia &
Upjohn, Uppsala, Sweden), improved the elasticity and
viscosity of synovial ﬂuid in the experimentally induced
osteoarthritic joints at 5 weeks after administration of the
last of ﬁve IA injections (week 26 of the study).
For example, in another in vitro study, Lisignoli et al.54
found that Hyalgan (sodium hyaluronate, MW
500e730 kDa), but not puriﬁed HAs with MW 40e65 kDa
or 1000 kDa, exerted an inhibitory effect on anti-Fas-
induced chondrocyte apoptosis. The effect was mediated
by speciﬁc HA binding to surface-expressed CD44 and
ICAM-1. In another in vitro study, a low-MW HA (200 kDa)
enhanced eosinophil production of transforming growth
factor, while a high-MW HA (3000e5800 kDa) had a sub-
stantially lesser impact55.
zBayer AG, Leverkusen, Germany; sold as Hyalgan in most of
Europe and US.
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Preclinical animal models of OA: disease-modifying effects of hyaluronans
Study Species Model Product/Regimen Results
Kikuchi et al.42 Rabbit Partial
meniscectomy
Artz [Supartz]*/IA injections
2!/week immediately after
surgery vs saline
HA produced a signiﬁcant
inhibition of cartilage degeneration
in femoral condyle and tibial
plateau 2 and 4 weeks after surgery
Armstrong et al.43 Sheep Meniscectomy Artz [Supartz]/5 weekly IA
injections starting at 16 weeks
postsurgery
HA limited development of changes
in articular cartilage and subchondral
bone
Wiig et al.46 Rabbit ACLT Healony/single injection
immediately after surgery vs
saline
HA produced pronounced tissue
repair, increased synthesis of collagen,
increased angiogenesis, and decreased
inﬂammation
Takahashi et al.38 Rabbit ACLT Artz[Supartz]/5 weekly IA
injections vs starting at 4 weeks
postsurgery vs saline
HA protected against chondrocyte
apoptosis
Amiel et al.49 Rabbit ACLT Hyalganz/5 weekly IA injections
starting at 4 or 13 weeks
postsurgery vs saline, with
follow-up at 26 weeks postsurgery
Single and repeat courses of HA
injections reduced the degree of
articular degeneration; repeat course
were best
Schiavinato
et al.50
Dog ACLT
(Pond-Nuki model)
Hyalgan/weekly IA injections vs
no surgery or no HA treatment,
assessed at 7 or 13 weeks
postsurgery
HA inhibited formation of ﬁbroblast-like
cell layer on the articular cartilage
and signiﬁcantly
increased mean chondrocyte density
and area in middle and deep layer
Wenz et al.51 Dog ACLT
(Pond-Nuki model)
Hyalart [Hyalgan]/5 weekly IA
injections starting at 3, 6, or 12
weeks after surgery vs saline
HA signiﬁcantly reduced cartilaginous
lesions
Marshall et al.48 Dog ACLT Synviscx/3 weekly IA injections,
starting 1 week after surgery
HA signiﬁcantly improved gross
morphology and histopathology
ACLT, anterior cruciate ligament transection; HA, hyaluronan; IA, intra-articular.
*Sodium hyaluronate, MW 620e1170 kDa, Seikagaku Corp., Tokyo, Japan.
ySodium hyaluronate, MW 1900e3900, Pharmacia & Upjohn Corp., Uppsala, Sweden.
zSodium hyaluronate, MW 500e730 kDa, Fidia SpA, Padua, Italy.
xHylan G-F 20, Biomatrix, Montreal, Canada.In contrast to studies in which HAs of intermediate MW
appeared to exert greater biological activity than HAs of
very low or high MW, two preclinical studies that used
a rabbit ACLT model of OA found otherwise. Shimizu
et al.56 compared the effects of three native HAs, Hyalgan
(sodium hyaluronate, MW 500e730 kDa), Artz (Supartz,
sodium hyaluronate, MW 800 kDa), Healon (sodium hya-
luronate, MW 3600 kDa)x, with a crosslinked form, Synvisc
(hylan G-F 20, MW 6000 kDa), on gross morphology and
histopathology. All of these HA forms exerted signiﬁcant
chondroprotective effects, but these effects were numeri-
cally superior in the groups receiving Synvisc and Healon.
In a similar rabbit ACLT study, Kikuchi et al.42 found that
whereas both forms of tested HAs produced signiﬁcant
chondroprotection, a fermented HA form of 1900 kDa
exerted superior protective protects compared with Artz
(Supartz, sodium hyaluronate, MW 800 kDa) in some
measures; for example, global femoral histopathologic
scores were superior in rabbits that received the higher-
MW HA form (P! 0.05). Similar biochemical experimental
evidence for a crucial role of HA MW in its biological activity
is accumulating rapidly, and is the subject of a recent in-
depth review30.
In the treatment of patients with OA of the knee, there is
no substantive clinical evidence to support the notion that
differences in MW (within the range of 500 to 6000 kDa) has
any impact on clinical efﬁcacy. Aviad and Houpt57
xPharmacia & Upjohn, Kalamazoo, MI; a form of sodium
hyaluronate indicated for intraocular use.examined this issue in a review of published HA clinical
studies and concluded that there was no substantive
evidence to suggest that differences in MW (within the
range of approved products on the market) had any
relationship to clinical efﬁcacy. The same conclusion was
reiterated in the American College of Rheumatology 2000
Treatment Guidelines for OA of the Knee58. However, this
issue has yet to be directly explored in the context of
potential disease-modifying activity.
CLINICAL STUDIES OF JOINT STRUCTURE
MODIFICATION BY HAs
The OARS has made a set of recommendations for the
conduct of clinical trials designed to investigate disease-
modifying drugs for the treatment of OA1. The primary
outcome of such trials should be a measure of joint
structure or morphology. Imagery (e.g., radiography or
magnetic resonance imagery) or direct visualization (e.g.,
arthroscopy) can be used. Studies that make use of
surrogate markers of cartilage destruction as an outcome
(such as in the study conducted by Creamer et al.33) are
considered helpful but not sufﬁcient for establishing
disease-modifying activity. Trials of at least 1 year in length
and, if possible, evaluation of patients at high risk for
progression are considered advantageous, as disease-
modifying effects may be slow-acting. For example,
a review of longitudinal studies using radiographs to follow
joint-space narrowing in osteoarthritic patients found the
average rate of change to be approximately 0.1 mm/year59.
220 V. M. Goldberg and J. A. Buckwalter: Disease-modifying activity of hyaluronans in OATable III
Clinical studies: disease-modifying activity of hyaluronans in knee OA
Study Design Product/Treatment Structural outcome
parameter
Results
Listrat et al.60 Randomized, 1-year,
no injection controlled
(nZ 36)
Hyalgan/arthroscopy followed
by 3 weekly IA injections every
3 months
Joint-space narrowing/
radiograph and ar-
throscopy
HA-treated patients showed less
deterioration of joint space than
did controls; difference did not
achieve signiﬁcance
Frizziero
et al.61
Open, 6-month study
(nZ 40)
Hyalgan/5 weekly IA
injections
Microarthroscopy and
morphological assess-
ment of paired biopsy
samples
HA produced signiﬁcant reconsti-
tution of superﬁcial amorphous
cartilage layer (PZ 0.0039), im-
provement in chondrocyte density
and vitality (PZ 0.0023 and
PZ 0.05), and reduction in syno-
vial inﬂammation (PZ 0.001)
Pasquali
Ronchetti
et al.62
Randomized, open,
active-controlled,
6-month study (nZ 24)
Hyalgan/5 weekly IA injections
vs methylprednisolone/3 weekly
injections
Arthroscopy with light
and electron micros-
copy
Both treatments signiﬁcantly de-
creased inﬂammatory score and
edema; HA reduced number and
aggregation of lining synoviocytes,
methylprednisolone decreased
number of mast cells (P% 0.05)
Guidolin
et al.63
Randomized, open,
active-controlled,
6-month study (nZ 24)
Hyalgan/5 weekly IA injections
vs methylprednisolone/3 weekly
injections
Analysis of paired
cartilage biopsies by
electron microscopy
HA produced signiﬁcant reconsti-
tution of superﬁcial layer, im-
proved chondrocyte density and
metabolism
Jubb et al.65 Multicenter, randomized,
placebo-controlled,
double-blind 1-year study
(nZ 319)
Hyalgan/3 courses of 3 weekly
IA injections vs saline
Change in joint space
measured by digital
image analysis of
weight-bearing
radiographs
HA reduced progression of joint-
space narrowing in patients with
greater joint-space width at entry
(PZ 0.02)
HA, hyaluronan; IA, intra-articular. Hyalgan [Hyalart] (sodium hyaluronate, MW 500e730 kDa), Fidia SpA, Padua, Italy.However, the rate of joint space loss may not be linear
throughout all stages of OA.
Recently results have become available from a number of
clinical studies that evaluated disease-modifying effects of
Hyalgan (sodium hyaluronate, MW 500e730 kDa). Each
of the studies described here used joint structure (assessed
via arthroscopy or radiographs) or morphology as the
outcome parameter, and several were carried out over at
least a 1-year period (Table III).
Arthroscopic and histomorphometric analysis
In a randomized, blinded, clinical trial carried out by
Listrat et al.60, a total of 39 patients with OA of the knee and
chondropathy underwent a baseline arthroscopic examina-
tion and were then treated with three cycles of 3 weekly IA
injections of Hyalgan (sodium hyaluronate, MW
500e730 kDa) or 3 weekly saline injections, at 4-month
intervals. A follow-up arthroscopic examination was per-
formed at the end of the 1-year study. Recorded videos of
the baseline and end-of-study arthroscopic examinations
were scored by blinded arthroscopists using a validated
scoring system of chondropathy (SFA) as the primary
outcome measure. This 1-year outcome measure is
consistent with those advocated by the OARS guidelines;
both blinded arthroscopy and radiography were evaluated.
The results demonstrated that patients who received
sodium hyaluronate had signiﬁcantly less progression of
chondropathy (visual analog scale [VAS] score of chondr-
opathy, PZ 0.016; SFA score, PZ 0.05) and a trend
toward less joint-space narrowing (not statistically signiﬁ-
cant due to small patient numbers), than did patients who
were treated with saline injections. In addition, even though
the primary outcome measure was progression of chondr-
opathy, the secondary outcome of clinical improvementbased upon the Arthritis Impact Measurement Scale (AIMS)
was signiﬁcantly better for the sodium hyaluronate treat-
ment group (P! 0.05) at 1 year. There was also a two-fold
less usage of rescue medication (paracetamol) by the HA
group, and a statistically signiﬁcant reduced usage of
NSAIDs (PZ 0.016).
An open-label study involving 40 patients with OA of the
knee was carried out to evaluate the effects of 5 weekly
injections of Hyalgan (sodium hyaluronate, MW
500e730 kDa) on synovial membrane and cartilage struc-
ture61. Outcomes were measured 6 months after initiation of
treatment. Microarthroscopic assessment, a visualization
process that allows magniﬁcations of up to 150 times the
normal arthroscopic ﬁeld, showed that 60% of patients
exhibited no progression and 32.5% of patients exhibited
improvement compared with baseline. Only 7.5% of
patients evaluated showed a worsened condition. Evalua-
tion of cartilage biopsy samples indicated a statistically
signiﬁcant reconstitution of the superﬁcial amorphous layer
of the cartilage (PZ 0.0039), an anatomical feature widely
applied in assessment of clinical condition in OA61,
improved chondrocyte density in cartilage biopsies
(PZ 0.0023) and vitality (a measure of chondrocyte
metabolic activity) (PZ 0.05), and reduction in synovial
inﬂammation (PZ 0.0001).
A randomized, open-label study conducted in 99 patients
with either primary or secondary OA of the knee compared
the effects of ﬁve IA injections of Hyalgan (sodium
hyaluronate, MW 500e730 kDa) with those of three
injections of methylprednisolone acetate62. The primary
outcome of this study, evaluated 6 months from the start of
treatment, was alteration in synovial membrane histopa-
thology, assessed using electron microscopic evaluation
of cartilage biopsies. Both active treatments signiﬁ-
cantly decreased inﬂammation and produced favorable
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membrane. Edema was decreased, and the amount of
collagen present in the membranes was increased. Sodium
hyaluronate, but not methylprednisolone, also signiﬁcantly
reduced the numbers of synoviocytes aggregating on the
synovial membrane, whereas methylprednisolone signiﬁ-
cantly decreased the numbers of mast cells present. When
cartilage biopsies were taken from a subset of 24 patients
with primary OA, results indicated that sodium hyaluronate
signiﬁcantly improved chondrocyte density (PZ 0.002 and
0.049 for zones I and II, respectively) and overall matrix
appearance (PZ 0.02), compared with methylprednisolone
treatment. Chondrocyte metabolism in HA-treated subjects
was also signiﬁcantly improved, as evidenced by increased
extension of synthetic structures and mitochondria63.
A second report described results of arthroscopic and
efﬁcacy evaluations of the 30 HA-treated and 25 methyl-
prednisolone-treated patients from the same study64. At the
6-month follow-up, a statistically signiﬁcant difference in
favor of HA was achieved for the reduction in lesion extent
in the medial tibial plateau (P! 0.03) and in lesion grade in
the patellar compartment (P! 0.02), but not for patients in
the methylprednisolone group. There was a tendency for
better improvement in the HA group for all other compart-
ments as well, which did not achieve statistical signiﬁcance.
Structural differences between the two treatment groups
were also maintained when evaluating patients with primary
OA separately. Although initially methylprednisolone pro-
duced a more immediate pain reduction effect measured
using VAS (evaluated at day 35 after treatment), the
symptomatic effect of HA appeared to be longer-lasting
based on VAS measurements at the 6-month follow-up. The
somewhat delayed, long-lasting, and pain-reducing effect of
HA as compared with methylprednisolone could reﬂect the
longer-term mechanisms of action that relate to an impact
on disease progression.
Radiography and JSW analysis
Because of the encouraging effects observed in these
small studies, a multicenter, double-blind, randomized study
involving 408 patients with OA of the knee was carried out
recently to assess the disease-modifying effects of Hyalgan
(sodium hyaluronate, MW 500e730 kDa)65. The primary
outcome parameter was the difference in JSW over 1 year,
measured using digital image analysis of standard weight-
bearing radiographs. Patients received three courses of 3
weekly IA injections of sodium hyaluronate or placebo
(saline) every 4 months, and were assessed at 1 year after
initiation of the treatment. A total of 319 patients completed
the 1-year study, but only 273 patients had paired evaluable
radiographs at baseline and at the 1-year follow-up based
upon prospective quality standards and that were assessed
by blinded radiologists. Prospectively, the patient popula-
tion (paired evaluable radiographs) was divided into
subpopulations for subsequent statistical analysis based
upon a mean JSW above the mean (less severe OA) and
those below the mean JSW (more severe OA), and an
analysis of covariance of these 273 patients demonstrated
that the response to treatment was indeed a function of the
baseline JSW. The study further demonstrated that sodium
hyaluronate treatment, compared with placebo, signiﬁcantly
reduced progression of loss of JSW in the subset of patients
who had higher joint-space area at study entry (O4.6 mm);
the HA group exhibited a mean loss of 0.13 mm, whereas
the placebo group showed a mean loss of 0.55 mm
(PZ 0.021). There was no statistical difference betweentreatment groups when comparing the change in JSW in the
patients with more severe OA based upon less JSW at
entry (!4.6 mm). Although all patients were allowed to
maintain their standard analgesic medications (paraceta-
mol, NSAIDs, etc.), the study also demonstrated statistically
signiﬁcant incremental beneﬁts of pain relief (beyond oral
analgesic use) compared with the control group at 2e4
months following each course of Hyalgan (sodium hyalur-
onate, MW 500e730 kDa) injections.
Discussion
Taken together, available clinical trial results form a solid
body of evidence in support of the ability of the one sodium
hyaluronate product evaluated in patients to modify OA
disease progression, and are consistent with a large body
of preclinical data demonstrating equivalent beneﬁts in
animal models for a number of HA products. Note that these
clinical studies made use of the OARS recommended
guidelines for the design of studies intended to demonstrate
disease modiﬁcation: the primary outcomes were based on
prospective evaluations of either imaged or directly visual-
ized measures of joint structure and morphology; in half of
the studies, outcomes were evaluated at the 1-year
timepoint (recommended duration)60,65. One important
issue that requires further information is the possible impact
of HA MW on disease-modifying activities. Current animal
data suggest that MW may be an important consideration,
but clinical data supporting disease modiﬁcation are
essentially limited to one HA product at present. Compar-
ative trials evaluating structural outcomes of treatment with
HA products of different size and manufacture are needed
to further investigate this issue.
The presumed underlying basis for disease-modifying
activity of HAsdwhich could include effects on synoviocyte
and chondrocyte function, cartilage degradation, endoge-
nous HA synthesis, and inﬂammatory processesdmay also
have important implications for therapeutic areas other than
OA. These include the use of HAs in related degradative
joint diseases such as chondromalacia, trauma injuries,
post-arthroscopy and post-surgical recovery, and for wound
healing. As an example, a recent study reported on the
beneﬁcial effects of sodium hyaluronate administered post-
arthroscopy or after open-knee joint procedures66. HA
mitigated inﬂammation, provided pain relief (assessed by
VAS), and enhanced range of motion. Other pilot studies
have also demonstrated beneﬁt of HA therapy in improving
function and/or reducing pain in patients following knee
immobilization67 or acute knee injury68, and in the treatment
of inﬂammatory arthropathies69. Deﬁnitive RCTs in each of
these indications are currently in progress.
The search for disease-modifying agents to treat OA has
become a priority in the ﬁeld of orthopedics. The nutritional
supplements glucosamine and chondroitin sulfate are
promising oral agents under evaluation. IA HAs have been
shown to be safe and efﬁcacious for treatment of pain of OA
of the knee; preliminary work supports HA use for OA pain
relief in other joints as well. Based on preclinical data, there
is evidence to support the notion that all the approved HAs
in the US may have some disease-modifying properties.
Growing clinical evidence also indicates that Hyalgan
(sodium hyaluronate, MW 500e730 kDa) may alter the
progression of OA. It would be of interest to see if similar
clinical beneﬁts can also be demonstrated with other HAs.
The possible underlying disease-modifying mechanisms of
action of HA, such as stimulation of chondrocyte growth and
222 V. M. Goldberg and J. A. Buckwalter: Disease-modifying activity of hyaluronans in OAmetabolism, inhibition of chondrodegradation, inhibition of
chondrocyte apoptosis, and suppression of destructive
inﬂammation, in conjunction with the unique physiochemical
properties of HA, may also allow applications to other
orthopedic therapeutic uses, such as post-arthroscopy
therapy, wound healing, and generation of synthetic
matrices for use in reconstructive surgery. Work is ongoing
in these areas.
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